Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL377049 | 1.00 | TSHR (0.32) | TSHRLMNATHRB | |
| SCHEMBL976968 | 1.00 | TSHR (0.32) | TSHRLMNATHRB | |
| SCHEMBL725620 | 0.85 | TSHR (0.38) | TSHRLMNATHRB | |
| SCHEMBL340710 | 0.85 | TSHR (0.38) | TSHRLMNATHRB | |
| SCHEMBL2110946 | 0.80 | TSHR (0.33) | TSHRLMNATHRB | |
| SCHEMBL2110949 | 0.80 | TSHR (0.33) | TSHRLMNATHRB | |
| SCHEMBL8884078 | 0.79 | — | — | |
| SCHEMBL3778589 | 0.76 | LMNA (0.30) | TSHRLMNA | |
| SCHEMBL5078419 | 0.76 | ALDH1A1 (0.30) | TSHRLMNA | |
| SCHEMBL6283644 | 0.76 | TSHR (0.32) | TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0431794-A2 | 3-Fluorosulfonyloxyceph-3-EM displacement process | Bristol-Myers Squibb Company (US) | 1991-06-12 | — | — | EP | claimed |
| US-4254145-A | LOCALIZED VASOCILATION | AMERICAN CYANAMID COMPANY (US) | 1981-03-03 | — | — | US | claimed |
| EP-0015658-A1 | Topical compositions containing prostaglandine derivatives | AMERICAN CYANAMID COMPANY (US) | 1980-09-17 | — | — | EP | claimed |
| EP-0008227-A1 | Pharmaceutical compositions for topical administration containing prostaglandins | AMERICAN CYANAMID COMPANY (US) | 1980-02-20 | — | — | EP | claimed |
| CN-118955503-A | Organic compound and organic electronic device comprising same | 广州追光科技有限公司 | 2024-11-15 | — | — | CN | disclosed |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ALTAVANT SCIENCES GMBH | 2023-09-19 | — | — | US | disclosed |
| WO-2023057645-A1 | METHODS FOR THE PRODUCTION OF SORANGICINS AND THEIR ANALOGUES | OTTO-VON-GUERICKE-UNIVERSITÄT MAGDEBURG (DE) | 2023-04-13 | — | — | WO | disclosed |
| US-20210255191-A1 | FLUORESCENT DYE AND USE THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-08-19 | — | — | US | disclosed |
| US-20210205305-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2021-07-08 | — | — | US | disclosed |
| US-10946018-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ROIVANT SCIENCES GMBH (CH) | 2021-03-16 | — | — | US | disclosed |
| US-20200237760-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ROIVANT SCIENCES GMBH (CH) | 2020-07-30 | — | — | US | disclosed |
| US-10660893-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ROIVANT SCIENCES, GmbH (CH) | 2020-05-26 | — | — | US | disclosed |
| EP-0343277-A1 | A process for the production of 3-hydrocarbyl-3-cephems | Bristol-Myers Squibb Company (US) | 1989-11-29 | — | — | EP | disclosed |
| EP-0334590-A2 | 3-(Substituted)-1-carba(dethia)-3-cephems and cephalosporins and a process for production therefor | ELI LILLY AND COMPANY (US) | 1989-09-27 | — | — | EP | disclosed |
| US-4870168-A | PALLADIUM COMPOUND AND TRIFURYLPHOSPHINE AS CATALYST | BRISTOL-MYERS COMPANY (US) | 1989-09-26 | — | — | US | disclosed |
| US-4855418-A | Process for production of ceophalosporins | ELI LILLY AND COMPANY (US) | 1989-08-08 | — | — | US | disclosed |
| US-4311707-A | PROSTAGLANDINS | AMERICAN CYANAMID COMPANY (US) | 1982-01-19 | — | — | US | disclosed |
| US-4254145-A | LOCALIZED VASOCILATION | AMERICAN CYANAMID COMPANY (US) | 1981-03-03 | — | — | US | disclosed |
| EP-0015658-A1 | Topical compositions containing prostaglandine derivatives | AMERICAN CYANAMID COMPANY (US) | 1980-09-17 | — | — | EP | disclosed |
| EP-0008227-A1 | Pharmaceutical compositions for topical administration containing prostaglandins | AMERICAN CYANAMID COMPANY (US) | 1980-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10660893-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | TSHR 1218/4885LMNA 2851/4885THRB 265/4885 |
| US-20200237760-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | TSHR 1218/4885LMNA 2851/4885THRB 265/4885 |
| US-20210205305-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | TSHR 1218/4885LMNA 2851/4885THRB 265/4885 |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | TSHR 1218/4885LMNA 2851/4885THRB 265/4885 |
| US-10946018-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | TSHR 1218/4885LMNA 2851/4885THRB 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.